IP Verse

Use Of Perfusion Seed Cultures To Improve Biopharmaceutical Fed-Batch Production Capacity And Product Quality

Patent No. EP3083933 (titled "Use Of Perfusion Seed Cultures To Improve Biopharmaceutical Fed-Batch Production Capacity And Product Quality") was filed by Biogen MA on Dec 19, 2014. The application was issued on Jan 21, 2026.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
COHAUSZ & FLORACKOct 21, 2026COHAUSZ & FLORACK
MAIWALD PATENTANWALTSOct 21, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
STORZOct 21, 2026MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBB
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBOct 20, 2026GRUNECKER PATENT
STRAWMANOct 20, 2026VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

EP3083933

BIOGEN MA
Application Number
EP14827357A
Filing Date
Dec 19, 2014
Status
Granted And Under Opposition
Dec 19, 2025
Publication Date
Jan 21, 2026
External Links
Slate, Register , Google Patents